Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
28.08.2007 15:45:00

Harvard Bioscience President David Green to Present at Thomas Weisel Partners Healthcare Conference in Boston on September 5, 2007

Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer, and marketer of a broad range of specialized products used to advance life science research, today announced that its President, David Green, will present at the Thomas Weisel Partners Healthcare Conference at 9:45 am local time on Wednesday, September 5, 2007 at the Four Seasons hotel in Boston. The presentation audio will be simultaneously webcast and will be accessible from the HBIO website www.harvardbioscience.com under the "Presentations & Webcasts" tab and at http://www.veracast.com/webcasts/twp/healthcare07/63104367.cfm until October 5, 2007. An archive of this presentation will also be available on our website. Mr. Green's presentation will be available at the conference or can be downloaded from our website by clicking on the investor presentation icon. The presentation will cover the historical and expected future performance of the business. There will be a question and answer session following the presentation. Some of the information to be presented by Mr. Green or provided in response to questions may contain information that has not previously been disclosed. Additionally, any material financial or other statistical information presented in our presentation or in the question and answer session, which has not been previously disclosed will be archived and available in the Investor Relations section of our website. About Harvard Bioscience Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily scientific instruments and apparatus, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. HBIO sells its products to thousands of researchers in over 100 countries, through its 1,100 page catalog (and various other specialty catalogs), its website and through its distributors, including GE Healthcare, Thermo Fisher Scientific and VWR. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany and Austria with additional facilities in France and Canada. For more information, please visit www.harvardbioscience.com. For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site, http://www.harvardbioscience.com.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Harvard Bioscience Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Harvard Bioscience Inc. 2,06 4,57% Harvard Bioscience Inc.

Indizes in diesem Artikel

NASDAQ Comp. 19 003,65 0,16%